Xcout Intel
Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc. is a private, clinical-stage biotechnology company based in San Diego, California, that develops engineered endothelial cell therapies.
Subscribe to see Angiocrine Bioscience, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Angiocrine Bioscience, Inc. at a glance
Angiocrine Bioscience, Inc. is a life science company headquartered in United States, founded in 2012. It has raised at least $60.2M across the 2 funding rounds on record. Its most recent funding round raised $2.1M in August 2025. Xcout tracks 11 named people at Angiocrine Bioscience, Inc., including Paul Finnegan, M.D., M.B.A. (Chief Executive Officer).
Angiocrine Bioscience, Inc. leadership
- Paul Finnegan, M.D., M.B.A.Chief Executive Officer
- Paul W. Finnegan, M.D.President and CEO
- John R JaskowiakChief Operating Officer
- John LomoroChief Financial Officer
- John K. Fraser, Ph.D.Chief Scientific Officer
- John R JaskowiakExecutive Officer
5 more named people on record for Angiocrine Bioscience, Inc., with roles, board committees and tenure — see the full roster →
Angiocrine Bioscience, Inc. funding rounds
At least $60.2M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $2.1M | — | |
| SEC Form D filing | $58.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Angiocrine Bioscience, Inc. competitors
A few of Angiocrine Bioscience, Inc.'s closest competitors — see the full list of competitors and alternatives →
Metacrine, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company builds a pipeline of differentiated therapies targeted at treating liver and gastrointestinal diseases.
AcroCyte Therapeutics, Inc. is a biotechnology company dedicated to overcoming common laboratory challenges through its proprietary R³CE rapid, reproducible, rare cell 3D expansion technology. Recognized with awards such as the Taiwan National Innovation Award, the company focuses on advancing biomedical research and cell-based applications.
Aspect Biosystems develops bioengineered cellular medicines and implantable tissue therapeutics using a proprietary bioprinting platform that integrates AI, computational design, and advanced biomaterials. The company serves the biotechnology and pharmaceutical industries by creating treatments to replace, repair, or supplement biological functions for metabolic and endocrine diseases.
VST Bio Corp. is a leader in the development of innovative biologics to treat acute and chronic cardiovascular diseases. Headquartered in San Diego, California, the company engages in drug pipelines, patents, and clinical trials.
Endogena Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Zürich, Switzerland, that discovers and develops first-in-class endogenous regenerative medicines to repair tissues.
Get Angiocrine Bioscience, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Angiocrine Bioscience, Inc. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access